Artificial Pancreas Systems Keep Working Well for Kids Over 3 Years, Real-World Study Shows

When a new diabetes technology is approved, doctors and families want to know: does it keep working well over years, not just months? A new study from 20 pediatric diabetes centers across Italy followed 359 children and teens using the MiniMed 780G automated insulin delivery system for three full years to answer that question.

The MiniMed 780G is an artificial pancreas system that automatically adjusts insulin delivery based on continuous glucose readings. This study tracked what happened in real-world use—not in a controlled research setting—which gives a clearer picture of how the technology performs for families managing daily life.

The headline finding: children and teens maintained excellent time in range (TIR)—the percentage of time their blood sugar stayed in the target zone—throughout the three-year period. Median time in range was 75% at one year and remained at 74% at three years, a decline of just one percentage point.

This stability is important because it shows the system didn't lose effectiveness as families used it longer. The small decline was gradual and remained well within the international targets that doctors consider optimal for young people with type 1 diabetes.

An interesting pattern emerged: over the three years, the way kids and teens used the device shifted. The system performed more automatic correction boluses (insulin adjustments it made on its own), while young people entered fewer carbohydrates and initiated fewer manual boluses themselves.

This suggests that as families became more comfortable with the technology, they relied more on the device's automatic features and less on manual inputs. However, the study also found an important detail: youth who had the best blood sugar control at year one showed a gradual decline in their results over time, though their numbers remained healthy. These young people also saw greater increases in automatic corrections.

The study identified two key factors tied to achieving the tightest blood sugar control at three years: using the system's SmartGuard feature (its automated protection against low blood sugar) consistently, and keeping device settings optimized. Youth whose systems were set up and maintained well were more than three times as likely to achieve the best outcomes compared to others.

These findings suggest that good setup from the start and ongoing attention to how the device is configured matter just as much as the technology itself. Regular check-ins with diabetes care teams to review and adjust settings may help families get the best results over the long run.

This three-year real-world study offers reassurance: automated insulin delivery systems don't lose effectiveness as time goes on. Young people who start using them can expect stable, strong blood sugar control if they stay engaged with the technology and keep their settings optimized.

The study also shows that the relationship between users and their devices evolves naturally. Over time, families tend to shift toward letting the automatic features do more of the work, which can reduce the mental burden of daily diabetes management—but only if the device is set up and maintained well. This underscores the importance of ongoing partnership with diabetes care teams, especially as users become more experienced.

Source: Diabetes technology & therapeutics. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.